Get started
Author

Fernando G. Ang

Observed names: FERNANDO ANG, Fernando Ang
Observed institution: Janssen Canada (Canada)
ORCID: 0009-0003-6075-4525
Observed ORCID: 0009-0003-6075-4525
OpenAlex ID: A5046205091
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
2024 · Sheldon W. Tobe, Thomas A. Mavrakanas, et al. · Diabetes Care · 15
PDF
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
2024 · Abhinav Sharma, Amir Razaghizad, et al. · Journal of the American Heart Association · 8
PDF
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
2023 · Vikas S. Sridhar, Brendon L. Neuen, et al. · Diabetes Obesity and Metabolism · 8
PDF
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
2023 · Tae Won Yi, Michelle M.Y. Wong, et al. · Diabetes Obesity and Metabolism · 7
PDF
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE
2023 · Michael A. Tsoukas, Vincent Woo, et al. · Diabetes Obesity and Metabolism · 2
PDF
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial
2023 · Abhinav Sharma, Pedro Marques, et al. · Diabetes Obesity and Metabolism · 1
PDF
Author response for "Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial"
2023 · Abhinav Sharma, Pedro Marques, et al. · Publons reviews and discussion
Effects of Canagliflozin (CANA) on Cardiovascular (CV), Kidney, and Albuminuria Outcomes by Diabetes Duration: Pooled Analysis From the CANVAS Program and CREDENCE
2022 · Sheldon W. Tobe, Harpreet S. Bajaj, et al. · Journal of the American Society of Nephrology
856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE
2022 · VINCENT C. WOO, MICHAEL TSOUKAS, et al. · Diabetes
FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial
2022 · Adeera Levin, Paul Poirier, et al. · Nephrology Dialysis Transplantation
PDF
Works count: 10
Citation count: 41
H-index: 4
I10-index: 1
Year
Topic
Type